MediciNova Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: San Diego CA United States (2000)

Organization Overview

First Clinical Trial
2005
NCT00295854
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

MediciNova | Medicinova Inc | MediciNova, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

Key: MediciNova (0) Acquired (1)

ibudilast (12 trials)

Drugs in Phase 2 Trials (5)

Key: MediciNova (3) Acquired (2)

adeno-associated viral with human factor ix (1 trial)

bedoradrine (5 trials)

temozolomide (temodar) (1 trial)

tipelukast (4 trials)

tolperisone (4 trials)

Drugs in Phase 1 Trials (2)

Key: MediciNova (0) Acquired (2)

fluvoxamine (luvox) (1 trial)

paroxetine (paxil) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alcohol Drinking (Phase 2)

Alcoholism (Phase 2)

Amyotrophic Lateral Sclerosis (Phase 3)

Asthma (Phase 2)

Cystitis (Phase 2)

Cystitis, Interstitial (Phase 2)

Fatty Liver (Phase 2)

Fibrosis (Phase 2)

Glioblastoma (Phase 2)

Hypercholesterolemia (Phase 2)

Hypertriglyceridemia (Phase 2)

Idiopathic Pulmonary Fibrosis (Phase 2)

Liver Diseases (Phase 2)

Lung Diseases (Phase 1)

Lung Diseases, Obstructive (Phase 1)

Motor Neuron Disease (Phase 3)

Multiple Sclerosis (Phase 2)

Multiple Sclerosis, Chronic Progressive (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Opioid-Related Disorders (Phase 2)

Pneumonia (Phase 2)

Pneumonia, Viral (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 1)

Pulmonary Fibrosis (Phase 2)

Sclerosis (Phase 3)

Status Asthmaticus (Phase 2)

Substance-Related Disorders (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 26
  • # of Trial APIs: 8